Publications

European urology

European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update.

27-04-2026

International journal of clinical oncology

Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.

01-03-2026

Nature reviews. Clinical oncology

From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer.

01-03-2026

European urology oncology

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.

01-02-2026

CA: a cancer journal for clinicians

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

13-12-2025

Nature medicine

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

01-12-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

20-11-2025

Annals of oncology : official journal of the European Society for Medical Oncology

Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.

01-10-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

15-09-2025

ESMO open

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

The Lancet. Oncology

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.

01-06-2025

Urologic oncology

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.

01-05-2025

Future oncology (London, England)

Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary.

01-03-2025

Cancer chemotherapy and pharmacology

Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.

25-02-2025

The New England journal of medicine

Perioperative Durvalumab in Bladder Cancer. Reply.

06-02-2025

European urology

FGFR Inhibition in Urothelial Carcinoma.

01-02-2025

Bladder cancer (Amsterdam, Netherlands)

Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes.

01-12-2024

European urology focus

Advancements in the front-line treatment of metastatic urothelial carcinoma.

01-12-2024

The New England journal of medicine

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

14-11-2024

BJC reports

Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.

23-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

13-09-2024

ESMO open

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria.

01-09-2024

BMC cancer

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.

25-07-2024

Journal of pharmaceutical and biomedical analysis

A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors, atezolizumab, avelumab, and durvalumab, in human serum.

15-06-2024

European urology

Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.

01-06-2024

Nature communications

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

21-03-2024

The New England journal of medicine

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

07-03-2024

European urology

Management of Lymph Node-positive Penile Cancer: A Systematic Review.

01-03-2024

Nature communications

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

14-02-2024

British journal of cancer

Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.

01-02-2024

The Lancet. Oncology

Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer.

01-02-2024

International journal of radiation oncology, biology, physics

Disease-Free Survival of Patients With Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder-Preserving Therapy: A Nationwide Study.

01-01-2024

Nature medicine

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-01-2024

Nature reviews. Urology

Turning up the heat: CTLA4 blockade in urothelial cancer.

01-01-2024

Nature medicine

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.

01-12-2023

The New England journal of medicine

Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.

09-11-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial.

01-11-2023

Frontiers in immunology

The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.

20-09-2023

Frontiers in oncology

Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.

15-09-2023

International journal of radiation oncology, biology, physics

A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma.

01-09-2023

Current opinion in urology

Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.

01-09-2023

BJU international

Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.

01-08-2023

European urology

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].

01-06-2023

European urology

European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.

01-06-2023

Cancer medicine

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

01-06-2023

European urology

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

01-04-2023

Bladder cancer (Amsterdam, Netherlands)

Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer.

31-03-2023

Nature medicine

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

01-03-2023

European urology

Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma.

01-01-2023